精准免疫治疗改善脓毒症结局:ImmunoSep随机临床试验
这项在6国开展的双盲、双模拟、安慰剂对照试验纳入281例脓毒症患者,按巨噬细胞活化样综合征或脓毒症诱导免疫麻痹表型给予阿那白滞素或重组人干扰素γ。
要点
- 以血铁蛋白>4420 ng/mL或≤4420 ng/mL且单核细胞HLA-DR<5000分型,指导阿那白滞素或干扰素γ治疗。
- 28天死亡率两组无统计学显著差异。
核心结论
- 在脓毒症患者中,依据巨噬细胞活化样综合征或脓毒症诱导免疫麻痹表型给予精准免疫治疗,可提高第9天SOFA评分下降≥1.4分的比例。
- 28天死亡率在精准免疫治疗组与安慰剂组之间无统计学显著差异。
研究设计与样本
- 随机、双盲、双模拟、安慰剂对照临床试验,在6个国家开展。
- 672例患者接受资格评估,281例被随机分组,276例纳入主要分析人群;平均(SD)年龄70(13)岁,女性93例(33.7%),基线SOFA评分中位数9(IQR 7–11)。
- 纳入标准为符合Sepsis-3的脓毒症,且伴社区获得性或医院获得性肺炎、呼吸机相关性肺炎或菌血症合并脓毒症,并显示巨噬细胞活化样综合征(血铁蛋白>4420 ng/mL)或脓毒症诱导免疫麻痹(血铁蛋白≤4420 ng/mL且CD45/CD14单核细胞HLA-DR受体<5000)。
- 首例患者入组2021年8月5日,末次随访2024年4月29日。
主要发现
- 28天死亡率两组间无统计学显著差异。
- 共报告1069例次严重治疗中出现的不良事件(88.8%)。
关键数值与推荐
- 巨噬细胞活化样综合征定义:血铁蛋白>4420 ng/mL。
- 脓毒症诱导免疫麻痹定义:血铁蛋白≤4420 ng/mL且CD45/CD14单核细胞HLA-DR受体<5000。
- 主要终点:第9天SOFA评分较基线平均下降≥1.4分;SOFA总分0–24分。
- 干预:巨噬细胞活化样综合征者静脉阿那白滞素加皮下安慰剂;免疫麻痹者皮下重组人干扰素γ加静脉安慰剂;安慰剂组接受静脉和皮下双安慰剂;治疗最长15天。
临床怎么用
- 对符合Sepsis-3的脓毒症患者,可检测血铁蛋白及单核细胞HLA-DR以区分巨噬细胞活化样综合征与免疫麻痹表型。
- 按表型分别给予阿那白滞素或重组人干扰素γ的精准免疫治疗,可能改善第9天器官功能,但未显示28天死亡率获益。
局限性
- 原文摘要未报告28天死亡率的具体数值及组间比较统计量。
- 原文摘要未报告严重治疗中出现的不良事件在两组间的具体分布。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
JAMA . 2026 Mar 3;335(9):775-786. doi: 10.1001/jama.2025.24175. ABSTRACT IMPORTANCE: Sepsis is heterogeneous, and the optimal strategy for tailoring immunotherapy is uncertain. OBJECTIVE: To investigate whether precision immunotherapy guided by the presence of macrophage activation-like syndrome or sepsis-induced immunoparalysis improves organ dysfunction by day 9. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, double-dummy, placebo-controlled clinical trial conducted in 6 countries. Patients with sepsis, defined by Sepsis-3, were included if they had community-acquired or hospital-acquired pneumonia or ventilator-associated pneumonia or bacteremia and sepsis and had displayed either macrophage activation-like syndrome (blood ferritin >4420 ng/mL) or sepsis-induced immunoparalysis (blood ferritin ≤4420 ng/mL and <5000 human leukocyte antigen DR receptors on CD45/CD14 monocytes). The first patient was enrolled August 5, 2021, and the last follow-up, April 29, 2024. INTERVENTIONS: Eligible patients were randomized to receive standard care and precision immunotherapy or standard care and placebo. Those in the precision immunotherapy group with macrophage activation-like syndrome received anakinra intravenously (IV) and placebo subcutaneously, and those with sepsis-induced immunoparalysis received subcutaneous recombinant human interferon gamma and IV placebo. Those in the placebo group received both IV and subcutaneous placebo. Treatment was administered for up to 15 days. MAIN OUTCOMES AND MEASURES: The primary end point was a decrease of at least 1.4 points in the mean Sequential Organ Failure Assessment (SOFA) score from baseline by day 9. The SOFA score evaluates 6 organ systems, ranging from 0, no dysfunction, to 4, failure, and the total score ranges from 0, normal, to 24, most severe form of multiorgan failure. Key secondary outcomes included 28-day mortality. RESULTS: Of 672 patients assessed for eligibility, 281 were randomized and 276 were included in the primary analysis population (mean [SD] age, 70 [13] years; 93 females [33.7%]; median baseline SOFA score, 9 [IQR, 7-11]). The SOFA decrease end point was attained by 46 of 131 patients (35.1%) in the precision immunotherapy group and by 26 of 145 patients (17.9%) in the placebo group (difference, 17.2% [95% CI, 6.8% to 27.2%]; P = .002). Mortality at 28 days was not statistically significantly different between groups. A total of 1069 serious treatment-emergent adverse events (88.8
引用
- PubMed 顶刊 · 肺炎:Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。